Related Experiment Video
Updated: Aug 3, 2025
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Clinical Trial Technologies for Improving Equity and Inclusion in Cardiovascular Clinical Research
Cassandra Broadwin1, Zahra Azizi1, Fatima Rodriguez2
1Center for Digital Health, Stanford University School of Medicine, Stanford, CA, USA.
Insights
Clinical trial recruitment challenges impact research integrity and patient outcomes. Emerging technologies and decentralized methods offer solutions to improve patient enrollment and reduce health disparities in cardiovascular medicine.
Area of Science:
- Cardiovascular Medicine
- Clinical Trial Design
- Health Equity
Background:
- One-third of clinical trials fail recruitment goals, leading to delays and compromising scientific validity.
- Insufficient patient group recruitment and retention hinder understanding of drug efficacy across diverse populations.
- Addressing recruitment disparities is crucial to prevent unequal risk distribution and ensure equitable access to research benefits.
Discussion:
- Emerging technologies can enhance patient identification and engagement for clinical trials.
- Decentralized clinical trial approaches offer flexibility and accessibility, potentially improving recruitment.
- Integrating technology and decentralized models can mitigate disparities in cardiovascular research.
Key Insights:
- Proactive strategies are needed to overcome clinical trial recruitment barriers.
- Technological advancements present novel opportunities for patient recruitment and retention.
- Decentralized models can improve trial inclusivity and generalizability.
Outlook:
- Future clinical trials should leverage technology and decentralized approaches for broader reach.
- Improved recruitment strategies will enhance cardiovascular medicine knowledge and patient care.
- Addressing disparities in clinical trials is essential for equitable health outcomes.
Abstract:
Approximately one-third of clinical trials fail to meet their recruitment goals, which can cause costly delays to sponsors and compromise the scientific integrity and generalizability of a trial. Inadequate recruitment and retention of patient groups who have the disease under investigation may produce insufficient medical knowledge about the therapeutic effects of drugs or products for the population at large. It is essential to address these issues to ensure that certain groups are not unduly subjected to disproportionate risks or denied the benefits of research. This commentary will present opportunities for clinical trialists to use emerging technologies and decentralized approaches to improve clinical trial recruitment, mitigate disparities, and improve individual and population-level outcomes within cardiovascular medicine.
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:20Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
01:11Blinding